1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,480 | 23,020 | 12:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 09:22 | JPMorgan startet Coverage für Caris Life Sciences mit "Overweight"-Rating | 2 | Investing.com Deutsch | ||
| 09:18 | JPMorgan initiates Caris Life Sciences stock with Overweight rating | 2 | Investing.com | ||
| 08:18 | Guggenheim initiates coverage on Caris Life Sciences stock with Buy rating | 3 | Investing.com | ||
| 08:10 | Guggenheim stuft Caris Life Sciences mit "Buy" ein und sieht 20 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 07:46 | Caris Life Sciences: BTIG startet Coverage mit "Buy" dank führender Rolle in der Präzisionsonkologie | 1 | Investing.com Deutsch | ||
| 07:42 | Caris Life Sciences stock initiated with Buy rating at BTIG on precision oncology leadership | 1 | Investing.com | ||
| So | BofA Securities initiates coverage on Caris Life Sciences stock with Buy rating | 4 | Investing.com | ||
| Di | Caris Life Sciences validates AI blood test for cancer detection | 1 | Investing.com | ||
| 24.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 24.06.2025 | 626 | Xetra Newsboard | The following instruments on XETRA do have their first trading 24.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.06.2025
Aktien
1 NL0015002J37 JBS N.V.
2 AU0000400616... ► Artikel lesen | |
| 23.06. | Should You Buy Caris Life Sciences Stock After the CAI IPO? | 8 | Barchart.com | ||
| 22.06. | Precision Medicine Firm Caris Breaks Bio IPO Drought, Raising $494M for Cancer Analysis Tools | 8 | MedCity News | ||
| 20.06. | Caris Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.06. | Stonebridge Capital Gains from Caris Nasdaq Listing | 2 | BusinessKorea | ||
| 18.06. | Caris Life Sciences trades higher on market debut | 6 | Seeking Alpha | ||
| 18.06. | Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut | 1 | Reuters | ||
| 18.06. | Caris Life Sciences Opens at $27, IPO Priced at $21 | 1 | Investing.com | ||
| 18.06. | Caris Life Sciences shares jump 29% in Nasdaq debut | 2 | Investing.com | ||
| 18.06. | Caris Life Sciences prices IPO at $21, above the upwardly revised range | 2 | Renaissance Capital | ||
| 18.06. | Caris Life Sciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.06. | Cancer diagnostics firm Caris prices IPO at $21 per share | 1 | Seeking Alpha |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINK THERAPEUTICS | 64,42 | 0,00 % | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 44,480 | 0,00 % | Kymera Therapeutics: Brookline Kapitalmärkte senkt Kursziel, belässt Einstufung aber auf "Buy" | ||
| AVIDITY BIOSCIENCES | 31,485 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,090 | 0,00 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,285 | 0,00 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
| EVOTEC | 7,018 | -0,40 % | Biotech Report: Qiagen geben ab, Evotec behauptet | (shareribs.com) Frankfurt / New York 07.07.2025 - Biotech-Aktie bewegten sich im deutschen Handel überwiegend nach unten. Qiagen verloren. An der Wall Street kommt es zu Kursverlusten. Auch der Biotech-Sektor... ► Artikel lesen | |
| PROKIDNEY | 4,540 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,150 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| COGENT BIOSCIENCES | 10,990 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,020 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| VOR BIOPHARMA | 2,520 | 0,00 % | Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer | Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass.,... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 15,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| PRIME MEDICINE | 4,345 | 0,00 % | Prime Medicine soars as Jones sees it as an acquisition target | ||
| ADMA BIOLOGICS | 18,500 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 38,140 | 0,00 % | Apogee Therapeutics: Kurssturz trotz Super-Daten! | Apogee Therapeutics liefert positive Studiendaten zu einem potenziellen Milliarden-Medikament. Doch nach anfänglicher Euphorie im vorbörslichen Handel wird die Aktie abverkauft. Vielversprechende 16-Wochen-Daten... ► Artikel lesen |
Das Unternehmen CARIS LIFE SCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,70 % bei einem Aktienkurs von 22,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARIS LIFE SCIENCES INC finden Sie auf Wallstreet Online.